How big Pharma companies structure their licensing deals – prepare for BIO 2012

Most companies dream about closing a licensing deal with big Pharma. But what do these deals really contain from a financial perspective and can any trends be found for potential big Pharma licensees in order to assist licensors in the deal making process?  To gain insight in these aspects, we have analyzed the financial deal … Continue reading How big Pharma companies structure their licensing deals – prepare for BIO 2012

Read more

Public Biotechs – Light at the end of the tunnel, although private Biotechs may have to wait a bit longer

Amsterdam March 2012: An overview of the state of the Biotech Industry was given by BIOs Industry Research & Analyst David Thomas at BIOEuropeSpring in Amsterdam. He made three main points: Public market have gained 25% in the last couple of month Private Biotechs still have a hard time to find investors Partnering and deal making … Continue reading Public Biotechs – Light at the end of the tunnel, although private Biotechs may have to wait a bit longer

Read more